Cellceutix Responds to Public Support by Expediting Autism Studies; Completes Two Required Safety Pharmacology Studies for Its Cancer Compound
June 7, 2010 | Press Releases
Cellceutix CFO Discusses Autism Drug, Kevetrin™ and Company Progressions With CEOCFO Interviews and News
June 3, 2010 | Press Releases
Cellceutix Signs Agreements for Kevetrin™ Phase 1 Support; Company Continues to Advance Kevetrin Toward Human Studies Targeting Drug Resistant Cancers
May 24, 2010 | Press Releases
Cellceutix Files Foreign Patent Application in PCT and Other Key Countries for Its Flagship Cancer Compound
May 18, 2010 | Press Releases
Recent Announcements Suggest Cellceutix Is Well Positioned With Autism Compound; Pfizer and Novartis Announcements Indicate Interest in Autism by Major Companies
May 12, 2010 | Press Releases
Cellceutix Presents Poster Session at AACR; Important New Data on Kevetrin™ in Resistant Lung Cancer Model Show Dose Response; No Tumor Cell Resistance With Second Cycle
April 21, 2010 | Press Releases
Cellceutix CEO Appears on ‘Stu Taylor on Business’: Cancer and Autism Compounds Are Discussed
April 12, 2010 | Press Releases
Cellceutix Announces Positive Results With Autism Compound KM-391, Showing Significant Improvements on Key Parameters in Animal Studies
March 29, 2010 | Press Releases